EPIDERMOLYSIS BULLOSA, JUNCTIONAL
Clinical trials for EPIDERMOLYSIS BULLOSA, JUNCTIONAL explained in plain language.
Never miss a new study
Get alerted when new EPIDERMOLYSIS BULLOSA, JUNCTIONAL trials appear
Sign up with your email to follow new studies for EPIDERMOLYSIS BULLOSA, JUNCTIONAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New gel offers hope for healing fragile skin in rare genetic condition
Disease control Recruiting nowThis study is testing whether Oleogel-S10 gel helps close wounds in people with two types of epidermolysis bullosa (EB), a rare genetic condition that causes fragile, blistering skin. Japanese children and adults with confirmed EB will apply the gel to their wounds for 45 days wh…
Matched conditions: EPIDERMOLYSIS BULLOSA, JUNCTIONAL
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Five-Year watch: does a Wound-Healing gel change skin cancer odds for Fragile-Skin patients?
Knowledge-focused Recruiting nowThis study aims to understand if using the topical gel Filsuvez affects the risk of developing skin cancers in people with severe forms of Epidermolysis Bullosa (EB), a condition that causes extremely fragile, blistering skin. Researchers will follow about 580 patients with EB fo…
Matched conditions: EPIDERMOLYSIS BULLOSA, JUNCTIONAL
Sponsor: Amryt Pharma • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC